Less than half of endocrinologists are impressed with Tzield’s ability to delay T1D (MARKETVUE® REPORT)
Sanofi/formerly Provention's Tzield (teplizumab), a CD3 mAb, is the only FDA-approved disease-modifying therapy that delays progression of Stage 2 T1D in patients 8 years and older. However, less than half [...]
There is significant need for efficacious membranous nephropathy treatments for high-risk patients (MARKETVUE® REPORT)
Nearly 1 in 5 membranous nephropathy patients never achieve remission, and nearly one-third of those that do will relapse. NEWTON, Mass., May 24, 2023 /PRNewswire/ -- Membranous nephropathy (MN) is a rare, [...]
Spevigo launch going well for Generalized Pustular Psoriasis (MARKETVUE® REPORT)
Boehringer-Ingelheim's intravenous Spevigo (spesolimab) is a therapy specifically indicated to treat active Generalized Pustular Psoriasis (GPP) flares. Nearly 90% of dermatologists with prior use reported spesolimab as very effective, according [...]
70% of classic homocystinuria patients are unhappy with their treatment (MARKETVUE® REPORT)
Drug development for homocystinuria is limited to just three clinical-stage products, two of which are injectable enzyme replacement therapies (ERTs). NEWTON, Mass., April 11, 2023 /PRNewswire/ -- Classic homocystinuria (HCU) is a [...]
Less than half of endocrinologists are impressed with Tzield’s ability to delay T1D (MARKETVUE® REPORT)
Sanofi/formerly Provention's Tzield (teplizumab), a CD3 mAb, is the only FDA-approved disease-modifying therapy that delays progression of Stage 2 T1D in patients 8 years and older. However, less than half [...]
There is significant need for efficacious membranous nephropathy treatments for high-risk patients (MARKETVUE® REPORT)
Nearly 1 in 5 membranous nephropathy patients never achieve remission, and nearly one-third of those that do will relapse. NEWTON, Mass., May 24, 2023 /PRNewswire/ -- Membranous nephropathy (MN) is a rare, [...]
Spevigo launch going well for Generalized Pustular Psoriasis (MARKETVUE® REPORT)
Boehringer-Ingelheim's intravenous Spevigo (spesolimab) is a therapy specifically indicated to treat active Generalized Pustular Psoriasis (GPP) flares. Nearly 90% of dermatologists with prior use reported spesolimab as very effective, according [...]
70% of classic homocystinuria patients are unhappy with their treatment (MARKETVUE® REPORT)
Drug development for homocystinuria is limited to just three clinical-stage products, two of which are injectable enzyme replacement therapies (ERTs). NEWTON, Mass., April 11, 2023 /PRNewswire/ -- Classic homocystinuria (HCU) is a [...]